AptarGroup マネジメント
マネジメント 基準チェック /44
AptarGroupの CEO はStephan Tandaで、 Feb2017年に任命され、 の在任期間は 9.25年です。 の年間総報酬は$ 10.23Mで、 11.5%給与と88.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.38%を直接所有しており、その価値は$ 29.66M 。経営陣と取締役会の平均在任期間はそれぞれ7.5年と7.6年です。
主要情報
Stephan Tanda
最高経営責任者
US$10.2m
報酬総額
| CEO給与比率 | 11.49% |
| CEO在任期間 | 9.3yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 7.5yrs |
| 取締役会の平均在任期間 | 7.6yrs |
経営陣の近況
Recent updates
分析記事 • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
ナラティブ更新 • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.ナラティブ更新 • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).ナラティブ更新 • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.
ナラティブ更新 • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.ナラティブ更新 • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
ナラティブ更新 • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.ナラティブ更新 • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).ナラティブ更新 • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).ナラティブ更新 • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.分析記事 • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...ナラティブ更新 • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.ナラティブ更新 • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).ナラティブ更新 • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).Seeking Alpha • Nov 02
AptarGroup: Pharma Setback Creates Long-Term Opportunities
Summary AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year. While the stock is approaching attractive valuation territory, risks remain for earnings growth in 2026, making the opportunity reasonable but not extremely compelling yet. Read the full article on Seeking Alphaナラティブ更新 • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.分析記事 • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...ナラティブ更新 • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.分析記事 • Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...分析記事 • Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45
AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...分析記事 • Jul 02
Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?
Key Insights AptarGroup's estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Current share price...分析記事 • Jun 19
These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • May 13
AptarGroup's (NYSE:ATR) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Dec 02
AptarGroup Has Gotten Too Expensive
Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha
新しいナラティブ • Aug 25
Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge
Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$387m |
| Dec 31 2025 | US$10m | US$1m | US$393m |
| Sep 30 2025 | n/a | n/a | US$419m |
| Jun 30 2025 | n/a | n/a | US$392m |
| Mar 31 2025 | n/a | n/a | US$370m |
| Dec 31 2024 | US$10m | US$1m | US$375m |
| Sep 30 2024 | n/a | n/a | US$336m |
| Jun 30 2024 | n/a | n/a | US$320m |
| Mar 31 2024 | n/a | n/a | US$313m |
| Dec 31 2023 | US$9m | US$1m | US$284m |
| Sep 30 2023 | n/a | n/a | US$281m |
| Jun 30 2023 | n/a | n/a | US$251m |
| Mar 31 2023 | n/a | n/a | US$232m |
| Dec 31 2022 | US$9m | US$1m | US$239m |
| Sep 30 2022 | n/a | n/a | US$238m |
| Jun 30 2022 | n/a | n/a | US$231m |
| Mar 31 2022 | n/a | n/a | US$223m |
| Dec 31 2021 | US$9m | US$1m | US$244m |
| Sep 30 2021 | n/a | n/a | US$240m |
| Jun 30 2021 | n/a | n/a | US$256m |
| Mar 31 2021 | n/a | n/a | US$243m |
| Dec 31 2020 | US$7m | US$1m | US$214m |
| Sep 30 2020 | n/a | n/a | US$209m |
| Jun 30 2020 | n/a | n/a | US$202m |
| Mar 31 2020 | n/a | n/a | US$234m |
| Dec 31 2019 | US$8m | US$1m | US$242m |
報酬と市場: Stephanの 総報酬 ($USD 10.23M ) は、 US市場 ($USD 8.41M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Stephanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Stephan Tanda (60 yo)
9.3yrs
在職期間
US$10,226,911
報酬
Mr. Stephan B. Tanda, MBA, has been an Independent Director at Ingredion Incorporated since August 19, 2019. He has been Chief Executive Officer and President at AptarGroup, Inc. since February 01, 2017. M...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 9.3yrs | US$10.23m | 0.38% $ 29.7m | |
| Executive VP & CFO | 1.3yrs | US$3.56m | 0.0020% $ 154.2k | |
| President of Aptar Pharma | no data | US$3.61m | 0.051% $ 4.0m | |
| President of Aptar Beauty | 7.7yrs | US$2.24m | 0.038% $ 3.0m | |
| Executive VP of Strategic Group Development & President of Aptar Asia | 7.6yrs | US$2.20m | 0.024% $ 1.9m | |
| President of Aptar Closures | 10yrs | US$2.62m | 0.039% $ 3.1m | |
| Senior VP & Chief Accounting Officer | 1.8yrs | データなし | 0.051% $ 4.0m | |
| Senior Vice President of Investor Relations & Communications | no data | データなし | データなし | |
| Executive VP | less than a year | データなし | 0.0030% $ 233.2k | |
| Chief Human Resources Officer | 7.5yrs | データなし | 0.048% $ 3.8m | |
| Head of Pharma Prescription | no data | データなし | データなし |
7.5yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: ATRの経営陣は経験豊富で経験豊富です（平均在職期間は7.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 9.3yrs | US$10.23m | 0.38% $ 29.7m | |
| Independent Director | 15yrs | US$270.99k | 0.0061% $ 478.2k | |
| Independent Director | 8.3yrs | US$296.99k | 0.014% $ 1.1m | |
| Independent Chairperson | 5yrs | US$406.02k | 0.0079% $ 621.4k | |
| Independent Director | 17yrs | US$266.99k | 0.025% $ 2.0m | |
| Independent Director | 16yrs | US$283.99k | 0.012% $ 929.8k | |
| Independent Director | 3.7yrs | US$278.99k | 0.011% $ 828.8k | |
| Independent Director | 7yrs | US$266.99k | 0.011% $ 892.2k | |
| Independent Director | 3.2yrs | US$266.99k | 0.0042% $ 330.3k | |
| Independent Director | 2.7yrs | US$270.99k | 0.0031% $ 245.7k |
7.6yrs
平均在職期間
59.5yo
平均年齢
経験豊富なボード: ATRの 取締役会 は 経験豊富 であると考えられます ( 7.6年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/07 03:16 |
| 終値 | 2026/05/07 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AptarGroup, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |